GFP variants
Patents for licensing
Never miss an update from Yeda
Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide
Summary of the technology
A collection of GFP variants with improved/unique properties, such as increased thermostability, photostability,
quantum yield, altered fluorescence lifetime, pH sensitivity, and excitation spectra.
Description
The team led by Prof. Fleishman developed a machine-learning-based approach called htFuncLib to design stable
mutations in proteins. They applied htFuncLib to the chromophore-binding pocket of eGFP, synthesized 11 million
designs in E. coli, and isolated 16,000 unique fluorescent designs encoding up to 12 active-site mutations relative
to eGFP. Among the designs, many exhibit large and useful diversity in thermostability, photostability, quantum
yield, fluorescence lifetime, pH sensitivity, and excitation spectra.
The collection offers a variety of stable GFP mutants, from which the optimal GFP can be selected based on the
experimental needs, for example, thermostability (including GFP variants active in various temperatures, over
90°c), altered fluorescence lifetime, and altered excitation spectra.
Related Keywords
About Yeda
Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.
WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.
Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.
Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.
Yeda performs the following activities:
◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.
Our portfolio covers a broad spectrum of the natural sciences, including:
◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools
Related Technology Offers
Send a request for information
to Yeda
About Technology Offers
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Help
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
